首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
【24h】

Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.

机译:低危分化型甲状腺癌治疗中甲状腺素治疗期间的甲状腺球蛋白测定:与重组人促甲状腺激素刺激测定和成像程序的比较。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Circulating human thyroglobulin (TG) measurement has a pivotal role in the management of patients affected by differentiated thyroid cancer (DTC). Undetectable thyrotropin (TSH)-stimulated serum TG after thyroid ablation (i.e., thyroidectomy and radioiodine) implies the absence of residual or relapsing DTC. Recently, high-cost recombinant human TSH (rhTSH) was proposed for TG stimulation to avoid uncomfortable thyroxine (T(4)) withdrawal. However, only a small fraction of relapsing DTC patients showed undetectable TG under T(4) treatment (onT(4)-TG) by high-sensitivity assays. The present study was undertaken to compare onT(4)-TG with the rhTSH-stimulated TG assay (rhTSH-TG), (131)I scanning and neck ultrasound (US) with fine-needle aspiration biopsy. METHODS: We enrolled 117 patients with histologically proven DTC treated by total thyroidectomy and radioiodine. Inclusion criteria were: complete tumour excision, no radioiodine uptake outside of the thyroid bed at post-treatment scan and undetectable onT(4)-TG 3 months after primary treatment. At 1 year after radioiodine treatment, all patients underwent onT(4)-TG assay, rhTSH-stimulated TG assay, (131)I scanning and neck US. Based on histology, clinical data and long-term follow-up, persistent/relapsing disease was confirmed in 14 patients. RESULTS: onT(4)- and rhTSH-TG were positive in 10 and 12 patients, respectively and two patients converted from undetectable to detectable TG after rhTSH administration. Neck US was positive in 10 patients and a combination of US with onT(4)- and rhTSH-TG assays showed positivity in 13 and 14 out 14 patients, respectively. A radioiodine scan was positive in six patients, all with positive onT(4)- and rhTSH-TG levels. Globally, the negative predictive value of the onT(4)- and rhTSH-TG assays was 99% and 100%, respectively, and 104 rhTSH stimulations had to be performed to detect one local recurrence with negative onT(4)-TG. CONCLUSIONS: Our preliminary data need further confirmation on larger groups of patients, but seem to indicate that onT(4)-TG assay by a high-sensitivity method combined with neck US may avoid rhTSH stimulation in low-risk DTC patients after surgery and radioiodine thyroid ablation.
机译:背景:循环人类甲状腺球蛋白(TG)的测量在受分化型甲状腺癌(DTC)影响的患者的管理中起着关键作用。甲状腺消融(即甲状腺切除术和放射性碘)治疗后,无法检测到促甲状腺激素(TSH)刺激的血清TG表示没有残留或复发的DTC。最近,高成本的重组人TSH(rhTSH)被提议用于TG刺激,以避免不适的甲状腺素(T(4))撤出。但是,只有一小部分复发性DTC患者在T(4)治疗下(onT(4)-TG)通过高灵敏度检测显示出无法检测到的TG。进行本研究,以比较onT(4)-TG与rhTSH刺激的TG分析(rhTSH-TG),(131)I扫描和颈部超声(US)细针穿刺活检。方法:我们纳入了经全甲状腺切除术和放射性碘治疗的117例经组织学证实的DTC的患者。纳入标准为:完全切除肿瘤,在治疗后扫描时甲状腺床外无放射性碘摄入,且在初次治疗后3个月在T(4)-TG上未检出。放射性碘治疗后1年,所有患者均接受了T(4)-TG测定,rhTSH刺激的TG测定,(131)I扫描和颈US检查。根据组织学,临床资料和长期随访,证实有14例患者患有持续性/复发性疾病。结果:分别在10例和12例患者中,onT(4)-和rhTSH-TG呈阳性,rhTSH给药后有2例患者的TG从无法检测变为可检测。 Neck US在10例患者中呈阳性,US与onT(4)-和rhTSH-TG分析的组合分别显示14例患者中有13例和14例为阳性。六例患者的放射性碘扫描均为阳性,所有onT(4)-和rhTSH-TG水平均为阳性。在全球范围内,onT(4)-和rhTSH-TG检测的阴性预测值分别为99%和100%,必须进行104次rhTSH刺激才能检测到onT(4)-TG阴性的局部复发。结论:我们的初步数据需要更多的患者群体进一步证实,但似乎表明通过高灵敏度方法结合颈部US进行onT(4)-TG测定可避免低风险DTC患者在接受手术和放射碘治疗后的rhTSH刺激甲状腺消融。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号